The clinical landscape of HIF2α inhibitors in oncology
HIF2α inhibitors show expanding promise across multiple cancer types, with growing understanding of how to predict who benefits and overcome drug resistance.
This comprehensive review from Dana-Farber/Harvard (Choueiri et al.) in Nature Reviews Clinical Oncology synthesizes the clinical development of HIF2α inhibitors from discovery of the PAS-B allosteric pocket to multiple regulatory approvals, covering belzutifan's clinical milestones and emerging next-generation agents including Phase 3 LITESPARK-011 data. Key challenges addressed include predictive biomarkers, primary/acquired resistance, on-target toxicities (anemia, hypoxia), and the expanding potential of HIF2α inhibition beyond kidney cancer to other hypoxia-adapted malignancies.
What the study was
- Study design
- Review
- Population
- Patients with VHL disease-associated tumors, clear-cell RCC, pheochromocytoma/paraganglioma, and other hypoxia-adapted malignancies
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Nature Reviews Clinical Oncology
Why it surfaced
High-impact review (Nat Rev Clin Oncol) by Choueiri et al. (world leader in RCC) synthesizing the entire HIF2α inhibitor landscape including multiple FDA approvals and Phase 3 data; qualifies as HIGH via NOVEL_TREATMENT flag despite review format; VHL disease intersection with rare disease watchlist adds further relevance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.